Nu-Med Plus (NUMD) Cash from Investing Activities (2012 - 2022)

Nu-Med Plus (NUMD) reported Cash from Investing Activities of $3000.0 for Q1 2022, up 299900.0% sequentially from $1.0 in Q4 2018.

Nu-Med Plus (NUMD) Cash from Investing Activities (2012 - 2022) Analysis & Trends

Nu-Med Plus (NUMD) has 5 years of Cash from Investing Activities data on file, last reported at $3000.0 in Q1 2022.

For the quarter ending Q1 2022, Cash from Investing Activities changed N/A year-over-year to $3000.0; the trailing twelve-month figure through Sep 2022 stood at $3000.0 (changed N/A YoY), and the FY2018 full-year result was -$5025.0, changed N/A from the prior year.
Cash from Investing Activities grew to $3000.0 in Q1 2022, from $1.0 in the prior quarter.
In the past five years, Cash from Investing Activities ranged from a high of $3000.0 in Q1 2022 to a low of -$5026.0 in Q2 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Investing Activities (Qtr)
1	Abbott Laboratories	182.32 Bn	175.02 Bn	6.27 Bn	-20.32 Bn
2	Stryker	128.75 Bn	125.88 Bn	3.81 Bn	-185.00 Mn
3	Medtronic	107.83 Bn	98.61 Bn	6.41 Bn	-917.00 Mn
4	Boston Scientific	67.61 Bn	66.15 Bn	3.61 Bn	-591.00 Mn
5	Edwards Lifesciences	48.13 Bn	44.45 Bn	1.29 Bn	-92.80 Mn
6	Dexcom	28.26 Bn	27.14 Bn	750.30 Mn	-298.50 Mn
7	GE HealthCare Technologies	27.78 Bn	25.50 Bn	1.98 Bn	-2.50 Bn
8	Smith & Nephew	26.99 Bn	26.41 Bn	-	-
9	Koninklijke Philips	23.92 Bn	20.80 Bn	2.07 Bn	-475.32 Mn
10	Nu-Med Plus	1.67 Mn	1.67 Mn	-	-

Download Data